- Home
- NGEN vs TLSA Comparison
NGEN vs TLSA Comparison
Compare NGEN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGEN | TLSA |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 145.1M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NGEN | TLSA |
|---|---|---|
| Price | $1.89 | $0.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $10.33 | $7.98 |
| AVG Volume (30 Days) | 466.3K | ★ 491.6K |
| Earning Date | 11-23-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $0.57 |
| 52 Week High | $5.97 | $1.90 |
Technical Indicators
Market Signals| Indicator | NGEN | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 68.67 | 29.22 |
| Support Level | $1.85 | $0.57 |
| Resistance Level | $2.32 | $1.21 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 92.42 | 4.32 |
Price Performance
Historical ComparisonAbout NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.